Fraxinellone

Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1[1].

Product Specifications

CAS Number

[28808-62-0]

UNSPSC

12352005

Hazard Statement

H301, H361

Target

HIF/HIF Prolyl-Hydroxylase; PD-1/PD-L1; STAT

Type

Natural Products

Related Pathways

Immunology/Inflammation; JAK/STAT Signaling; Metabolic Enzyme/Protease; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/fraxinellone.html

Concentration

10mM

Purity

99.99

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1O[C@@H](C2=COC=C2)[C@]3(C)CCCC(C)=C31

Molecular Formula

C14H16O3

Molecular Weight

232.28

Precautions

H301, H361

References & Citations

[1]Xing Y, et al. Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1α and STAT3. Pharmacol Res. 2018 Sep;135:166-180.